Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05451849 · FLOW

Participant flow

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer · Source last updated 2026-07-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Eligible participants underwent leukapheresis to manufacture engineered T cells. Prior to dosing, participants had to remain eligible and, prior to dosing, were given lymphodepleting chemotherapy (fludarabine and cyclophosphamide). Six (6) participants were dosed once with a mean total of 50.7 x 10\^7 TC-510 T cells (mITT population). All subjects completed the interventional phase of the trial.
    id
    FG000
    title
    Phase 1
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Did not meet eligibility criteria prior to lymphodepletion and dosing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        6
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Fourteen (14) participants were screened and subsequently underwent leukapheresis in Phase 1 (Intent-to-Treat population). Six (6) participants received lymphodepleting chemotherapy and were dosed in Phase 1 (modified Intent-to-Treat population). No participants were subsequently included in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.
Complete source fields
groups
  1. description
    Eligible participants underwent leukapheresis to manufacture engineered T cells. Prior to dosing, participants had to remain eligible and, prior to dosing, were given lymphodepleting chemotherapy (fludarabine and cyclophosphamide). Six (6) participants were dosed once with a mean total of 50.7 x 10\^7 TC-510 T cells (mITT population). All subjects completed the interventional phase of the trial.
    id
    FG000
    title
    Phase 1
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Did not meet eligibility criteria prior to lymphodepletion and dosing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        6
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        8
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Fourteen (14) participants were screened and subsequently underwent leukapheresis in Phase 1 (Intent-to-Treat population). Six (6) participants received lymphodepleting chemotherapy and were dosed in Phase 1 (modified Intent-to-Treat population). No participants were subsequently included in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice